Long-Term Weight Loss and Metabolic Syndrome Remission after Bariatric Surgery: The Effect of Sex, Age, Metabolic Parameters and Surgical Technique – A 4-Year Follow-Up Study

AbstractIntroduction: Data on long-term patterns of weight change in relation to the development of metabolic syndrome (MetS) are scarce. The aim of the study was to evaluate the impact of weight change on the risk of MetS in men. Material and Methods: Prospective longitudinal observation (17.9 ± 8.1 years) of apparently healthy 324 men aged 18–64 years. Metabolic risk was assessed in weight gain (⩾ 2.5 kg), stable weight (> −2.5 kg and < 2.5 kg) and weight loss (⩽ −2.5 kg) groups. Adjusted relative risk (RR) of MetS was analyzed using multivariate logistic regression. Results: The prevalence of MetS over follow-up was 22.5%. There was a strong relationship between weight gain and worsening of MetS components among baseline overweight men. Long-term increase in weight was most strongly related with the risk of abdominal obesity (RR=7.26; 95% CI 2.98–18.98), regardless of baseline body mass index (BMI). Weight loss was protective against most metabolic disorders. Leisure-time physical activity (LTPA) with energy expenditure > 2000 metabolic equivalent/min/week was associated with a significantly lower risk of MetS. Conclusions: Reducing weight among overweight and maintaining stable weight among normal-weight men lower the risk of MetS. High LTPA level may additionally decrease the metabolic risk regardless of BMI.

Download Full-text

MANAGEMENT OF ENDOCRINE DISEASE: Metabolic effects of bariatric surgery

Acta Endocrinologica ◽

10.1530/eje-15-0533 ◽

2016 ◽

Vol 174 (1) ◽

pp. R19-R28 ◽

Cited By ~ 15

Author(s):

Ricard Corcelles ◽

Christopher R Daigle ◽

Philip R Schauer

Keyword(s):

Cardiovascular Disease ◽

Bariatric Surgery ◽

Metabolic Syndrome ◽

Weight Loss ◽

Metabolic Effects ◽

Perioperative Morbidity ◽

Increased Risk ◽

Long Term Impact

Obesity is associated with an increased risk of type 2 diabetes, hypertension, dyslipidemia, cardiovascular disease, osteoarthritis, numerous cancers and increased mortality. It is estimated that at least 2.8 million adults die each year due to obesity-related cardiovascular disease. Increasing in parallel with the global obesity problem is metabolic syndrome, which has also reached epidemic levels. Numerous studies have demonstrated that bariatric surgery is associated with significant and durable weight loss with associated improvement of obesity-related comorbidities. This review aims to summarize the effects of bariatric surgery on the components of metabolic syndrome (hyperglycemia, hyperlipidemia and hypertension), weight loss, perioperative morbidity and mortality, and the long-term impact on cardiovascular risk and mortality.

Download Full-text

Effect of Bariatric Surgery-Induced Weight Loss on Platelet Count and Mean Platelet Volume: a 12-Month Follow-Up Study

Obesity Surgery ◽

10.1007/s11695-016-2292-z ◽

2016 ◽

Vol 27 (2) ◽

pp. 387-393 ◽

Cited By ~ 11

Author(s):

Loïc Raoux ◽

David Moszkowicz ◽

Karina Vychnevskaia ◽

Tigran Poghosyan ◽

Alain Beauchet ◽

...

Keyword(s):

Bariatric Surgery ◽

Weight Loss ◽

Platelet Count ◽

Mean Platelet Volume ◽

Platelet Volume ◽

Follow Up Study

Download Full-text

CARDIAC I-123 METAIODOBENZYLGUANIDINE IMAGING PREDICTS THE RISK OF CARDIAC DEATH IN PATIENTS WITH CHRONIC HEART FAILURE, IRRESPECTIVE OF THE METABOLIC SYNDROME.: A LONG TERM FOLLOW UP STUDY

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(12)61172-3 ◽

2012 ◽

Vol 59 (13) ◽

pp. E1171

Author(s):

Hironori Yamamoto ◽

Takahisa Yamada ◽

Takashi Morita ◽

Yoshio Furukawa ◽

Koji Tanaka ◽

...

Keyword(s):

Heart Failure ◽

Metabolic Syndrome ◽

Chronic Heart Failure ◽

Cardiac Death ◽

Follow Up Study ◽

The Metabolic Syndrome ◽

Long Term Follow Up

Download Full-text

Weight and Glycemic Control Outcomes of Bariatric Surgery and Pharmacotherapy in Patients With Melanocortin-4 Receptor Deficiency

Frontiers in Endocrinology ◽

10.3389/fendo.2021.792354 ◽

2022 ◽

Vol 12 ◽

Author(s):

Esphie Grace Fodra Fojas ◽

Saradalekshmi Koramannil Radha ◽

Tomader Ali ◽

Evan P. Nadler ◽

Nader Lessan

Keyword(s):

Bariatric Surgery ◽

Weight Loss ◽

Glycemic Control ◽

Therapeutic Interventions ◽

Control Group ◽

Short Term ◽

Melanocortin 4 Receptor ◽

Significant Difference

BackgroundMelanocortin-4 receptor (MC4R) mutations are the most common of the rare monogenic forms of obesity. However, the efficacy of bariatric surgery (BS) and pharmacotherapy on weight and glycemic control in individuals with MC4R deficiency (MC4R-d) is not well-established. We investigated and compared the outcomes of BS and pharmacotherapy in patients with and without MC4R-d.MethodsPertinent details were derived from the electronic database among identified patients who had BS with MC4R-d (study group, SG) and wild-type controls (age- and sex-matched control group, CG). Short- and long-term outcomes were reported for the SG. Short-term outcomes were compared between the two groups.ResultsSeventy patients were screened for MC4R-d. The SG [six individuals (four females, two males); 18 (10–27) years old at BS; 50.3 (41.8–61.9) kg/m2 at BS, three patients with homozygous T162I mutations, two patients with heterozygous T162I mutations, and one patient with heterozygous I170V mutation] had a follow-up duration of up to 10 years. Weight loss, which varied depending on mutation type [17.99 (6.10–22.54) %] was stable for 6 months; heterogeneity of results was observed thereafter. BS was found superior to liraglutide on weight and glycemic control outcomes. At a median follow-up of 6 months, no significant difference was observed on weight loss (20.8% vs. 23.0%, p = 0.65) between the SG and the CG [eight individuals (four females, four males); 19.0 (17.8–36.8) years old at BS, 46.2 (42.0–48.3) kg/m2 at BS or phamacotherapeutic intervention]. Glycemic control in patients with MC4R-d and Type 2 diabetes improved post-BS.ConclusionOur data indicate efficacious short-term but varied long-term weight loss and glycemic control outcomes of BS on patients with MC4R-d, suggesting the importance of ongoing monitoring and complementary therapeutic interventions.

Download Full-text

Binge eating scores pre-bariatric surgery and subsequent weight loss: A prospective, 5 years follow-up study

Clinical Nutrition ESPEN ◽

10.1016/j.clnesp.2020.05.013 ◽

2020 ◽

Vol 38 ◽

pp. 146-152

Author(s):

Natalia Luiza Kops ◽

Manoela Astolfi Vivan ◽

Mariana L. Dias de Castro ◽

Jaqueline D. Correia Horvath ◽

Fabiana Silva Costa ◽

...

Keyword(s):

Bariatric Surgery ◽

Weight Loss ◽

Binge Eating ◽

Follow Up Study

Download Full-text

2083-P: Monogenic Obesity Mutations Lead to Less Weight Loss after Bariatric Surgery: A 6-Year Follow-Up Study

Diabetes ◽

10.2337/db19-2083-p ◽

2019 ◽

Vol 68 (Supplement 1) ◽

pp. 2083-P

Author(s):

CHENG HU

Keyword(s):

Bariatric Surgery ◽

Weight Loss ◽

Monogenic Obesity ◽

Follow Up Study

Download Full-text

Comparative Effectiveness of Gastric Bypass and Vertical Sleeve Gastrectomy for Hypertension Remission and Relapse: The ENGAGE CVD Study

Hypertension ◽

10.1161/hypertensionaha.120.16934 ◽

2021 ◽

Author(s):

Kristi Reynolds ◽

Lee J. Barton ◽

Anirban Basu ◽

Heidi Fischer ◽

David E. Arterburn ◽

...

Keyword(s):

Bariatric Surgery ◽

Weight Loss ◽

Gastric Bypass ◽

Sleeve Gastrectomy ◽

Vertical Sleeve Gastrectomy ◽

Variable Approach ◽

Study Population ◽

Instrumental Variable Approach

Weight loss is an effective strategy for the management of hypertension, and bariatric surgery is the most effective weight loss and maintenance strategy for obesity. The importance of bariatric surgery in the long-term management of hypertension and which operation is most effective is less clear. We compared the effectiveness of vertical sleeve gastrectomy (VSG) and Roux-en-Y gastric bypass (RYGB) for remission and relapse of hypertension after surgery in the ENGAGE CVD cohort study (Effectiveness of Gastric Bypass Versus Gastric Sleeve for Cardiovascular Disease). Operations were done by 23 surgeons across 9 surgical practices. Hypertension remission and relapse were assessed in each year of follow-up beginning 30 days and up to 5 years postsurgery. We used a local instrumental variable approach to account for selection bias in the choice of VSG or RYGB. The study population included 4964 patients with hypertension at the time of surgery (n=3186 VSG and n=1778 RYGB). At 1 year, 27% of patients with RYGB and 28% of patients with VSG achieved remission. After 5 years, without accounting for relapse, 42% of RYGB and 43% of VSG patients had experienced hypertension remission. After accounting for relapse, only 17% of RYGB and 18% of VSG patients remained in remission 5 years after surgery. There were no statistically significant differences between VSG and RYGB for hypertension remission, relapse, or mean systolic and diastolic blood pressure at any time during follow-up.

Download Full-text